Cancer Immunotherapy - MSc

at London Metropolitan University

Modular structure

The modules listed below are for the academic year 2022/23 and represent the course modules at this time. Modules and module details (including, but not limited to, location and time) are subject to change over time.

Year 1 modules include:
 

• Advanced Immunology (core, 20 credits)
• Cancer Immunotherapy (core, 20 credits)
• Cancer Pharmacology (core, 20 credits)
• Cancer: Diagnosis and Therapy (core, 20 credits)
• Molecular Oncology (core, 20 credits)
• Research Project (core, 60 credits)
• Scientific Frameworks For Research (core, 20 credits)

You will be required to have:
 

• at least a lower second (2.2) UK first degree (or equivalent) in an appropriate subject, for example pharmacology, biomedical science, biological science or medical genetics (these will be considered on an individual basis)

English language requirements
To study a degree at London Met, you must be able to demonstrate proficiency in the English language. If you require a Student visa you may need to provide the results of a Secure English Language Test (SELT) such as Academic IELTS.

UK Students

Costs
£9,300 per year

Overseas Students

Cost
£16,500 per year

Additional costs
 

• Please note, in addition to the tuition fee there may be additional costs for things like equipment, materials, printing, textbooks, trips or professional body fees.
• Additionally, there may be other activities that are not formally part of your course and not required to complete your course, but which you may find helpful (for example, optional field trips). The costs of these are additional to your tuition fee and the fees set out above and will be notified when the activity is being arranged.

As a graduate of this course, you’ll be well prepared to work for companies that are developing cancer immunotherapies. Such companies include global biopharmaceutical company Bristol-Myers Squibbs, MERCK, AstraZeneca and Roche. There are also an an ever-growing number of start-up companies that are tackling cancer, including Vyriad, UNUM Therapeutics and Alpine Immune Sciences.

You’ll also have ample opportunity for future postgraduate study within the School of Human Sciences and the Cellular and Molecular Immunology Research Centre at the MPhil/PhD level, as well as research opportunities with partners within the UK, Europe and the rest of the world.